Pfizer’s stock took a sharp dip on May 28, dropping over 2% to $23.12 by the afternoon. The stock opened flat at $23.61 but ...

Shares of Pfizer Inc. PFE slid 1.82% to $23.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to 5,888.55 and Dow ...

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. The group holding the most ...

Pfizer Limited’s stock price surged 28% last month and 18% over the past year, raising eyebrows despite subdued future growth ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

This is where InvestingPro’s powerful stock screener comes in. Among its many pre-built tools, the “ Cash is King ” screener stands out for investors who prioritize financial strength. It identifies ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...